WHEN:
Thursday, September 17, 2026
8:15am – 4:30pm
WHERE:
TBD
Tucson, AZ 85750
KEYNOTE:
Reisa Sperling, MD
Professor of Neurology, Harvard Medical School
Director, Center for Alzheimer Research and Treatment
Brigham and Women’s Hospital and Massachusetts General Hospital
Dr. Reisa Sperling is a neurologist focused on the detection and treatment of Alzheimer’s disease (AD) at the earliest possible stage, even before clinical symptoms are apparent. Dr. Sperling is a Professor in Neurology at Harvard Medical School, and the Director of the Center for Alzheimer Research and Treatment (CART) at Brigham and Women’s Hospital and Massachusetts General Hospital. Dr. Sperling is the co-Principal Investigator (with her husband Keith Johnson) of the NIH funded Harvard Aging Brain Study. Dr. Sperling chaired the 2011 NIA-Alzheimer’s Association workgroup to develop guidelines for the study of “Preclinical Alzheimer’s disease,” and co-led the workgroup that defined “Amyloid Related Imaging Abnormalities (ARIA) the same year. She co-led the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) Study, the first prevention trial is sporadic preclinical (“presymptomatic”) AD, and the companion LEARN Study, and has made the A4/LEARN longitudinal data publicly available to researchers from around the world. Dr. Sperling co-leads the NIH funded Alzheimer’s Clinical Trial Consortium (ACTC), and the public-private partnership AHEAD 3-45 Study prevention trials, testing targeted dosing of lecanemab in early and late stages of preclinical AD, as well as the Alzheimer Plasma Extension (APEX) Study working towards primary prevention trials for AD.
PLUS:
Poster presentations
Data blitz presentations
Wrap-up session